The trial enrolled about 300 patients to assess progression free survival rates, overall survival, duration of response and side effects. The study did not find any new safety issues, Takeda said in an Oct. 2 news release, nor did it meet the FDA’s benchmark for confirmatory trials among accelerated approval products.
In 2021, the FDA granted the drug accelerated approval for adult patients with epidermal growth factor receptor Exon20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy, according to the release.
Takeda said it is working with regulators in other countries to determine “next steps.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
